Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Netflix Plans All-Cash Bid for Warner Bros Discovery Studios Amid Intense Hollywood Takeover Battle 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
AFT Leaves X Over AI-Generated Images of Minors 
Coca-Cola Shelves Costa Coffee Sale After Low Private Equity Offers 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit 
IRVINE, Calif., March 30, 2017 -- Khang & Khang LLP (the “Firm”) announces a class action lawsuit against Stemline Therapeutics, Inc. (“Stemline” or the “Company”) (Nasdaq:STML). Investors who purchased shares of the Company either (1) pursuant and/or traceable to Stemline’s secondary public offering on or about January 20, 2017; and/or (2) publicly traded on the open market between January 19, 2017 and February 1, 2017 inclusive (the “Class Period”) are encouraged to contact the Firm prior to the April 4, 2017 lead plaintiff motion deadline.
If you purchased shares of Stemline during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at [email protected].
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
The Complaint alleges that during the Class Period, Stemline made false and/or misleading statements and/or failed to disclose that a cancer patient in a Stemline clinical trial tied to SL-401 died from a severe side effect on January 18, 2017; and thus, the Company’s statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. On February 2, 2017, Bloomberg disclosed that a patient in a clinical trial of Stemline’s cancer drug SL-401 died from a side effect. This is the third death linked to SL-401 toxicity. When this information was announced to the public, the value of Stemline stock fell significantly, causing investors severe harm.
If you wish to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact: Khang & Khang LLP Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
